Creo Medical Regulatory News (CREO)

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Welsh Labour Leader visits Creo's design and manufacturing facilities in Chepstow

Creo Medical Group plc (AIM: CREO), the Chepstow based medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, was pleased to welcome Vaughan Gething MS, the Welsh Labour leader and colleagues, to its design and manufacturing facilities in Chepstow, Wales on Monday 18 March 2024.

During the visit Creo was able to showcase its pioneering endoscopic surgical solutions, which introduce advanced energy to endoscopy in new markets and procedures, facilitating an array of benefits to patients, clinicians and healthcare providers. Creo is an Innovation-led Welsh company, rolling out cutting-edge medical technology that utilises high-frequency microwave energy and dynamic matching techniques for cancer treatment. Creo's technology can be used to treat Bowel, Oesophagus, Stomach, Lung, Pancreas, Liver cancer, whilst reducing waiting times and hospital backlog at a lower cost than traditional surgical procedures and treatments.

Vaughan Gething, who is set to be confirmed as the First Minister of Wales later this week, visited the site in his capacity as Leader of the Welsh Labour Party, along with Jo Stevens, MP for Cardiff Central; Shadow Secretary of State for Wales; and Catherine Fookes, Labour parliamentary candidate for Monmouthshire. Vaughan Gething previously visited Creo Medical's Chepstow Headquarters in his capacity as Economy Minister in 2023.

The presentation delivered at yesterday's meeting is available to view here:

https://www.creomedical.com/en/investors/reports-and-presentations

The Welsh Government provided support to the business via its Economy Futures Fund, to create 85 jobs while expanding its premises and investing in state-of-the-art manufacturing equipment.

The Development Bank of Wales have also been strong supporters of the business and remains a significant shareholder of the Company. Creo has also received considerable support from local Angel Investors and UK Institutional Investors. These investments have allowed Creo to grow its workforce, creating well paid jobs in Chepstow.

Craig Gulliford, Chief Executive Officer of Creo, commented: "Creo is a great example of a dynamic Welsh business at the very forefront of Medtech device innovation, developing pioneering surgical devices that are being rolled out globally, and transforming the way in which cancer can be treated. We welcome the Welsh Government's continued support for our business and have been delighted to demonstrate to the Welsh Labour Party leader, The Shadow Secretary of State for Wales, and colleagues, the exciting opportunity we have as a Welsh business to become a world-leader in this emerging field of endoscopic surgery."

Shadow Secretary of State for Wales, Jo Stevens MP said: "Creo Medical is a fantastic example of how the Welsh Labour government is backing home-grown businesses to create well paid, skilled jobs.

"Their ground-breaking medtech innovations transform the surgical experience for clinicians and patients. Welsh Government support has allowed them to grow their business creating new, well-paid jobs here in Wales. 

"With a Labour government at both ends of the M4, we will get our economy growing and modernise our NHS."

Enquiries:

About Creo Medical 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com